{"id":"NCT04838613","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Diagnostic Performance of [18F]CTT1057 in BCR","officialTitle":"Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence (BCR)]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-30","primaryCompletion":"2023-11-23","completion":"2023-11-23","firstPosted":"2021-04-09","resultsPosted":"2025-03-12","lastUpdate":"2025-04-13"},"enrollment":190,"design":{"allocation":"NA","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Prostatic Neoplasms","Prostate Cancer","Recurrence"],"interventions":[{"type":"DRUG","name":"[18F]CTT1057","otherNames":[]},{"type":"DRUG","name":"[68Ga]Ga-PSMA-11","otherNames":[]}],"arms":[{"label":"PET/CT imaging with [18F]CTT1057 followed by [68Ga]Ga-PSMA-11 or vice versa","type":"EXPERIMENTAL"}],"summary":"The current study aimed at evaluating the diagnostic performance of \\[18F\\]CTT1057 as a PET imaging agent for detection and localization of Prostate specific membrane antigen (PSMA) positivity in patients diagnosed of biochemical recurrence of prostate cancer (PCa), using a composite truth standard.\n\nApproximately 190 participants were to be enrolled to ensure at least 152 participants were evaluable (i.e. have both an evaluable \\[18F\\]CTT1057 Positron emission tomography/Computed Tomography (PET/CT) scan imaging and at least one evaluable Composite Truth Standard (CTS) assessment and had not received any prohibited systemic antineoplastic therapy before the completion of PET/CTs and CTS procedures, which were required for the calculation of the co-primary endpoints.","primaryOutcome":{"measure":"Region-level Correct Localization Rate (CLR) of Vidoflufolastat (18F)","timeFrame":"vidoflufolastat (18F) PET imaging acquired at Day 1 or Day 15 assessed against Composite Truth Standard (CTS) obtained within 8 weeks (before or after) of 18F-CTT PET scan or during follow-up (up to 90 days after radiotherapy for PSA level assessment)","effectByArm":[{"arm":"Central Reader 1","deltaMin":67.8,"sd":null},{"arm":"Central Reader 2","deltaMin":73.3,"sd":null},{"arm":"Central Reader 3","deltaMin":67.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":13,"countries":["United States","France","Spain","Switzerland"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=2417"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":171},"commonTop":["Asthenia","COVID-19","Lipase increased","Amylase increased","Blood creatine phosphokinase increased"]}}